About Us
Welcome
Welcome to NanoMed Solution LLC, where we are committed to designing and developing innovative pharmaceutical nanotechnology products. Our team of experts provides services ranging from pre-formulation studies and pre-clinical research stages to phase 2 clinical trials for INDA, NDA/BLA regulatory submission, and 510K/PMA applications.
Our extensive experience in targeted nanoparticle delivery allows us to provide cutting-edge solutions that meet the needs of our clients. We take pride in our ability to deliver high-quality results promptly and cost-effectively. At NanoMed Solution LLC, we believe innovation is critical to success and strive to stay at the forefront of the pharma industry.
Our Team of Experts
At NanoMed Solution, we are proud to have a team of highly experienced scientific investigators and clinical pharmacists leading our efforts in pharmaceutical nanotechnology. With over 20 years of combined experience in academia, pharmaceutical industry , and hospitals, our interdisciplinary leadership team brings a wealth of expertise to every project we undertake.
Led by world expert Prof. Dr. Tamer Biomi, M.S., Ph.D., our team includes experts in drug delivery systems, nanomaterials, and clinical pharmacology. Each member of our team is dedicated to staying at the forefront of their respective fields, ensuring that we are always using the most cutting-edge technology and techniques to develop novel pharmaceutical products.
Why Choose Us
At NanoMed Solution LLC, we are committed to providing our clients with the highest level of expertise in nanomedicine. Our team of experienced scientists and clinical pharmacists brings over 20 years of combined academic, industry, and hospital experience to every project we undertake.
We pride ourselves on our dedication to innovation and cutting-edge technology. Our approach to pharmaceutical nanotechnology is focused on developing novel targeted nanoparticle delivery products that meet the unique needs of our clients while also pushing the boundaries of what is possible in this field. We are dedicated to ensuring our client's complete satisfaction with every aspect of our services.
Nanomedicine Revolution
Pharmaceutical nanotechnology is a rapidly evolving field that has the potential to revolutionize the pharmaceutical industry. At NanoMed Solution LLC, we understand the importance of staying at the forefront of this technology to provide our clients with the most advanced solutions. We can help our clients develop more effective and efficient targeted drug delivery systems by leveraging our expertise in this area.
Nanoparticles, liposomes, nanocrystals, and other nanostructures offer unique advantages over traditional drug delivery methods. They can improve bioavailability, enhance targeting, and reduce toxicity. Our team of experts can help our clients navigate the complex world of pharmaceutical nanotechnology and identify the best solutions for their specific needs.
Success Stories
- One of our recent projects involved developing a targeted nanoparticle delivery system for a drug used to treat skin cancer. The client had been struggling with a peptide-based drug's poor solubility and bioavailability, which limited its effectiveness. Our team of experts worked closely with the client to design and optimize a nanotechnology-based formulation that significantly improved the drug's performance. In preclinical studies, the new formulation showed higher efficacy and better pharmacokinetic properties than the original drug. The client was extremely satisfied with the results and is now moving forward with INDA.
- Another project we worked on focused on developing an extended-release formulation for a drug product to treat chronic inflammation and pain. The client wanted to improve patient compliance by reducing the dosing frequency and minimizing side effects. Our team used a combination of advanced lipid polymers and nanotechnology to develop a formulation that achieved the desired longer-release profile and minimized toxicity. The new nano-formulation showed comparable efficacy to the standard formulation in preclinical studies. Yet, the nanoformulation showed a significantly longer plasma half-life, which reduced dosing frequency and was associated with fewer side effects. The client has used these data to extend the patent life of their product.
Interdisciplinary nanoscience solutions for pharma R&D
Chief Executive Officer: Amy Nayel, D.Ph., MPA, CJCP, FASCP
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
Dr. Amy Nayel is a highly accomplished Clinical Pharmacist with extensive clinical investigation leadership experience, and research record. She has a bachelor’s degree in Pharmaceutical Science, a dual Master's Degree in Public Administration and Health Care Management from Grand Canyon University, and a Doctorate in Pharmacy from Oklaho
Dr. Amy Nayel is a highly accomplished Clinical Pharmacist with extensive clinical investigation leadership experience, and research record. She has a bachelor’s degree in Pharmaceutical Science, a dual Master's Degree in Public Administration and Health Care Management from Grand Canyon University, and a Doctorate in Pharmacy from Oklahoma State. Moreover, she received a Post-Doctorate Fellowship from the American Society of Consultant Pharmacists (ASCP) and a Collaborative Institutional Training Initiative (CITI) Diploma from Dana Farber/Harvard University. In addition to being a licensed Pharmacist in multiple states, Dr. Nayel serves as a Panel Judge for PGY1/PGY2 Pharmacy Residents and a Scientific Panel Reviewer for the American Association of Colleges of Pharmacy (AACP) Award Proposals. Dr. Nayel’s clinical pharmacy specialization includes Medication Therapy Management (MTM), USP <797>, and USP <800> IV-Aseptic Technique, plus being a Certified Joint Commission Professional (CJCP). She has over 20 years of experience in various clinical positions, including Adjunct Assistant Professor of Pharmacy Practice, Clinical Pharmacist at Teaching/Research Hospital, and Pharmacy Manager at Home Infusions Center and Ambulatory Care Facilities. Her clinical trial and regulatory expertise include Investigational New Drugs (IND)/Clinical trials (Phase III-Pre-Market & Phase IV-Post Market), Sterile Compounding Standards, Aseptic Technique, Hospitals Accreditation, and Survey Readiness.
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
An Expert in Nanomedicine & Drug Delivery - Formulation Sciences and pre/Clinical Product Development - with over 20 years of combined academic and pharmaceutical industry experience. Dr. Biomi is a Tenured Full Professor of Pharmaceutical Sciences and Founding Codirector of The Nanomedicine Center of Excellence (COE) at Midwestern Unive
An Expert in Nanomedicine & Drug Delivery - Formulation Sciences and pre/Clinical Product Development - with over 20 years of combined academic and pharmaceutical industry experience. Dr. Biomi is a Tenured Full Professor of Pharmaceutical Sciences and Founding Codirector of The Nanomedicine Center of Excellence (COE) at Midwestern University, Glendale, AZ. He's also a Pharmaceutical product and clinical pharmacology partner/consultant for several national and international pharma companies and a professional nanomedicine educator.
Dr. Biomi completed his Post-Doctoral Fellowship at the Center of Pharmaceutical Biotechnology and Nanomedicine after receiving his Ph.D. in Pharmaceutical Sciences from Northeastern University, Boston, MA. Before joining the faculty at Midwestern University, he held the position of Sr. Formulation Research Scientist, R&D Cardiology Systems at Atrium Medical/Getinge Corp., Merrimack, NH. Dr. Biomi has published numerous research papers, review articles, and book chapters, focusing on nanomedicines and targeted nanocarrier delivery systems for therapeutics and imaging agents. His areas of interest include translational cardiovascular therapy, investigational cancer chemotherapy, anti-inflammatory immunomodulation, and targeted contrast agents for diagnostic imaging.
Clinical Pharmacology Director: Molly Yao, M.S., Ph.D.
Chief Scientific Officer: Tamer Biomi (Elbayoumi), R.Ph., M.S., Ph.D.
Clinical Pharmacology Director: Molly Yao, M.S., Ph.D.
An accomplished industry and academic expert in pre-clinical expert in pre-clinical/INDA modeling and evaluation. She obtained her bachelor’s degree in chemistry from a top university in China and continued her studies with a master’s degree in chemistry at the Rochester Institute of Technology, NY. She then pursued a Ph.D. in Pharmacolog
An accomplished industry and academic expert in pre-clinical expert in pre-clinical/INDA modeling and evaluation. She obtained her bachelor’s degree in chemistry from a top university in China and continued her studies with a master’s degree in chemistry at the Rochester Institute of Technology, NY. She then pursued a Ph.D. in Pharmacology from Creighton University's School of Medicine, Omaha, NE. Dr. Yao's post-doctoral training at the University of Pittsburgh's Vascular Medicine Institute in PA focused on investigating the molecular mechanisms underlying pulmonary heart disease and kidney ischemia-reperfusion (IRI) injury. She is dedicated to identifying new drug targets and developing novel APIs, with a focus on regenerative therapies that promote tissue and organ repair through stimulating angiogenesis and counteracting immuno-inflammation. Dr. Yao is experienced in the pre-clinical validation of new APIs through translational studies using in vivo, ex vivo, ex ovo, and in vitro models. Her recent published work has resulted in the development of a short peptide-based drug candidate that specifically antagonizes the detrimental effects of pathological extracellular matrix protein against the endothelium of vital organs, including the heart, liver, lungs, and kidneys. She has successfully developed this recombinant protein into a parenteral nanomedicine prototype via bio-conjugation with an FDA-approved liposomal platform, currently in pre/clinical studies for regulatory submission.